Arai Hiroyuki, Elliott Andrew, Xiu Joanne, Wang Jingyuan, Battaglin Francesca, Kawanishi Natsuko, Soni Shivani, Zhang Wu, Millstein Joshua, Sohal Davendra, Goldberg Richard M, Hall Michael J, Scott Aaron J, Khushman Moh'd, Hwang Jimmy J, Lou Emil, Weinberg Benjamin A, Marshall John L, Lockhart Albert C, Stafford Phillip, Zhang Jian, Moretto Roberto, Cremolini Chiara, Korn W Michael, Lenz Heinz-Josef
Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
Clinical and Translational Research, Medical Affairs, Caris Life Sciences, Phoenix, Arizona.
Clin Cancer Res. 2021 Jun 1;27(11):3234-3242. doi: 10.1158/1078-0432.CCR-20-3635. Epub 2021 Mar 25.
Defective DNA damage response (DDR) is a hallmark of cancer leading to genomic instability and is associated with chemosensitivity. Although the mismatch repair system has been extensively studied, the clinical implications of other mechanisms associated with DDR alterations in patients with colorectal cancer remain unclear. This study aimed to understand DDR pathways alterations and their association with common clinical features in patients with colorectal cancer.
Next-generation sequencing and whole-transcriptome sequencing were conducted using formalin-fixed paraffin-embedded samples submitted to a commercial Clinical Laboratory Improvement Amendments-certified laboratory. Samples with pathogenic or presumed pathogenic mutations in 29 specific DDR-related genes were considered as DDR-mutant (DDR-MT) and the remaining samples as DDR-wild type (DDR-WT).
Of 9,321 patients with colorectal cancer, 1,290 (13.8%) were DDR-MT. The frequency of DDR-MT was significantly higher in microsatellite instability-high (MSI-H) cases than in microsatellite stable cases (76.4% vs. 9.5%). The DDR-MT genotype was higher in the right-sided, -wild, -mutant, and CMS1 subgroups. However, these associations were primarily confounded by the distribution of MSI status. Compared with the DDR-WT tumors, the DDR-MT tumors had a higher mutational burden and gene expression levels in the immune-related pathway, which were independent of MSI status.
We characterized a distinct subgroup of patients with colorectal cancer with tumors harboring mutations in the DDR-related genes. These patients more commonly had MSI-H tumors and exhibited an activated immune signature regardless of their tumor's MSI status. These findings warrant further investigations to develop personalized treatment strategies in this significant subgroup of patients with colorectal cancer.
DNA损伤反应(DDR)缺陷是癌症的一个标志,可导致基因组不稳定,并与化疗敏感性相关。尽管错配修复系统已得到广泛研究,但在结直肠癌患者中,与DDR改变相关的其他机制的临床意义仍不明确。本研究旨在了解DDR通路改变及其与结直肠癌患者常见临床特征的关联。
使用提交给一家获得商业临床实验室改进修正案认证的实验室的福尔马林固定石蜡包埋样本进行下一代测序和全转录组测序。在29个特定DDR相关基因中存在致病性或推测致病性突变的样本被视为DDR突变型(DDR-MT),其余样本为DDR野生型(DDR-WT)。
在9321例结直肠癌患者中,1290例(13.8%)为DDR-MT。微卫星高度不稳定(MSI-H)病例中DDR-MT的频率显著高于微卫星稳定病例(76.4%对9.5%)。DDR-MT基因型在右侧、野生型、突变型和CMS1亚组中更高。然而,这些关联主要受MSI状态分布的混淆。与DDR-WT肿瘤相比,DDR-MT肿瘤在免疫相关通路中具有更高的突变负担和基因表达水平,且与MSI状态无关。
我们对结直肠癌患者中一个独特的亚组进行了特征描述,该亚组患者的肿瘤在DDR相关基因中存在突变。这些患者更常见的是MSI-H肿瘤,并且无论其肿瘤的MSI状态如何,都表现出激活的免疫特征。这些发现值得进一步研究,以在此重要的结直肠癌患者亚组中制定个性化治疗策略。